Kalohexis Announces Publication in Nature Communications Highlighting Dual MC3R/MC4R Activation as a Novel, Durable Mechanism that Drives Weight Loss

Dual Activation of MC3R and MC4R Drives Weight Loss and Reduces Food Intake in Male Primates with Obesity NORTHBROOK, Ill., May 29, 2026 /PRNewswire/ -- Kalohexis, a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care...